Baxter makes $380M grab for Baxa to boost IV and oral delivery
This article was originally published in Scrip
Executive Summary
Baxter once again plans to add to its IV solutions business – this time through the acquisition Baxa Corporation for $380 million in cash. Baxa is a privately held company that has developed pharmacy devices and software that improves the safety of oral and IV dose preparation and delivery.